Thymic Stromal Lymphopoietin Amplifies the Differentiation of Alternatively Activated Macrophages

Hongwei Han, Mark B. Headley, Whitney Xu, Michael R. Comeau, Baohua Zhou and Steven F. Ziegler

J Immunol published online 28 December 2012
http://www.jimmunol.org/content/early/2012/12/28/jimmunol.1201808

Supplementary Material http://www.jimmunol.org/content/suppl/2013/01/04/jimmunol.1201808.DC1

Why The JI? Submit online.
- Rapid Reviews! 30 days* from submission to initial decision
- No Triage! Every submission reviewed by practicing scientists
- Fast Publication! 4 weeks from acceptance to publication

*average

Subscription Information about subscribing to The Journal of Immunology is online at:
http://jimmunol.org/subscription

Permissions Submit copyright permission requests at:
http://www.aai.org/About/Publications/JI/copyright.html

Author Choice Freely available online through The Journal of Immunology
Author Choice option

Email Alerts Receive free email-alerts when new articles cite this article. Sign up at:
http://jimmunol.org/alerts
Thymic Stromal Lymphopoietin Amplifies the Differentiation of Alternatively Activated Macrophages

Hongwei Han,* Mark B. Headley,*,† Whitney Xu,* Michael R. Comeau,‡ Baohua Zhou,§ and Steven F. Ziegler,*†

The epithelial-derived cytokine thymic stromal lymphopoietin (TSLP) has been associated with the promotion of type 2 inflammation and the induction of allergic disease. In humans TSLP is elevated in the lungs of asthma patients and in the lesional skin of individuals with atopic dermatitis, whereas mice lacking TSLP responses are refractory to models of Th2-driven allergic disease. Although several cell types, including dendritic cells, basophils, and CD4 T cells, have been shown to respond to TSLP, its role in macrophage differentiation has not been studied. Type 2 cytokines (i.e., IL-4 and IL-13) can drive the differentiation of macrophages into alternatively activated macrophages (aaMφs, also referred to as M2 macrophages). This population of macrophages is associated with allergic inflammation. We therefore reasoned that TSLP/TSLPR signaling may be involved in the differentiation and activation of aaMφs during allergic airway inflammation. In this study, we report that TSLP changes the quiescent phenotype of pulmonary macrophages toward an aaMφ phenotype during TSLP-induced airway inflammation. This differentiation of airway macrophages was IL-13-, but not IL-4-, dependent. Taken together, we demonstrate in this study that TSLP/TSLPR plays a significant role in the amplification of aaMφ polarization and chemokine production, thereby contributing to allergic inflammation. The Journal of Immunology, 2013, 190: 000–000.

Macrophages are innate immune cells with well-established roles in primary responses to pathogens, tissue homeostasis, coordination of adaptive immune responses, inflammation, resolution, and tissue repair (1, 2). Depending on the microenvironment, macrophage differentiation and function are governed by numerous cell-extrinsic factors, including cytokines, chemokines, and TLRs (3). For example, classically known macrophage (M1 macrophage) activation is induced by IFN-γ, which triggers the proinflammatory responses required to kill intracellular pathogens, including Leishmania and Salmonella (4). In contrast, macrophages can undergo alternative activation by IL-4 and IL-13, triggering an immune response important for parasite elimination. These Th2 cytokines promote the differentiation of alternatively activated macrophages (aaMφs), characterized by abundant expression of mannose receptor (MR, or CD206), with increased levels of MHC class II and a panel of signature genes, including arginase 1 (Arg1), chitinase-like molecules (Ym1/2 and AMCase), and resistin-like molecule α (2, 5–9). Although the recruitment of aaMφs is a characteristic inflammatory feature of parasitic infection, allergy, diabetes, and cancer (10–14), the potential roles of aaMφs in influencing the development, severity, or resolution of inflammatory responses have remained controversial. Furthermore, IL-4 and IL-13 selectively induce CCL17 (TARC), CCL22 (MDC), and CCL24 (eotaxin-2) in aaMφs but are inhibited by IFN-γ (15–17). The CCR4 agonist CCL17, produced by aaMφs, along with IL-10 inhibits the generation of classically activated macrophages (18).

Recently, thymic stromal lymphopoietin (TSLP), an IL-7–related cytokine, has emerged as an important potential contributor to allergic inflammation (19). The involvement of TSLP in dysregulated Th2 responses was first demonstrated in atopic dermatitis (AD) patients, as skin biopsies from AD lesions showed greatly enhanced levels of TSLP protein compared with normal and nonlesional skin (20). Additionally, human asthmatics have increased concentrations of TSLP in their airways, which correlates with Th2-attracting chemokine expression and disease severity (21). A more causative relationship between TSLP and Th2 cytokine–mediated disease was established with transgenic overexpression models. Induced epidermal TSLP expression leads to a spontaneous AD-like disease characterized by many of the hallmark features of human AD (22). In contrast, TSLPR-deficient mice exhibited a dramatically reduced Th2 inflammatory response in an FITC-mediated contact hypersensitivity model of AD (23). Mice expressing lung-specific TSLP developed severe airway inflammation (24) whereas mice deficient in the TSLPR failed to develop asthma in the classic OVA prime/challenge model (24, 25).

Although it is becoming clear that TSLP is an important determinant in allergic inflammation, the mechanisms underlying this effect remain unclear. In this study we demonstrate that TSLP is a hitherto unrecognized amplifier of aaMφ polarization, and that TSLP-activated aaMφs significantly contribute to type 2 immune responses both locally and systemically.
Materials and Methods

**Mice**

Six- to 8-wk-old female BALB/c mice were obtained from Charles River Laboratories. SPC-TSLP mice were generated as described previously (24). K5-TSLP mice were generated as described previously (22, 26). IL-4 knockout (KO; Il4−/−), IL-4Rα KO (Il4ra−/−), and STAT6 KO (Stat6−/−) mice were purchased from The Jackson Laboratory. IL-13 KO (Il13−/−) mice were provided by Dr. Andrew McKenzie (Medical Research Council, Cambridge, U.K.). All animals were housed in specific pathogen-free conditions at the Benaroya Research Institute (Seattle, WA) animal facility. Experimental protocols were approved by the Institutional Animal Care and Use Committee of Benaroya Research Institute.

**Preparation of peritoneal macrophages and bone marrow–derived macrophages**

Peritoneal cells were obtained by sterile lavage with RPMI 1640 supplemented with 2% heat-inactivated FCS (HyClone Laboratories, Logan, UT) and antibiotics. Peritoneal macrophages were isolated and sorted according to the phenotype F4/80+ and CD19−.

Bone marrow cells were isolated from femurs and cultured with RPMI 1640 supplemented with 10% FBS and 10% L929 conditioned medium. Culture fluid was exchanged for fresh culture medium every 4 d. Under these conditions, adherent macrophage monolayers were obtained within 8–10 d. Mouse bone marrow–derived macrophages (BMDMs) were then stimulated with IL-4, IL-13, IFN-γ (all 10 ng/ml; PeproTech), LPS (10 ng/ml; Sigma-Aldrich), and TSLP (20 ng/ml; gift of A. Morgen, Amgen), or in combination.

**OVA sensitization and airway challenge**

Wild-type (WT) and Tslpr−/− mice were sensitized on days 1 and 14 by i.p. injection of 50 μg OVA (A7642; Sigma-Aldrich) emulsified in 1.3 mg aluminum hydroxide (Alum) gel (Sigma-Aldrich) in a total volume of 200 μl. Anesthetized mice were challenged intranasally (i.n.) with 50 μg OVA in 40 μl PBS on days 21, 22, and 23. Mice were sacrificed 3 h following Ag challenge on days 21 and 22 as well as 24 and 48 h after final challenge. Serum, bronchoalveolar lavage (BAL) cells, and lungs were harvested and analyzed.

**Intranasal treatment**

Anesthetized animals were administered 500 ng TSLP i.n. or 25 μg mouse serum albumin (MSA; Sigma-Aldrich) with 25 μg OVA (A7642; Sigma-Aldrich) in a total volume of 40 μl in PBS. Following i.n. administration, mice were suspended in an upright position for 10 min to ensure complete uptake of the treatment solution (27).

**Ab treatment**

M1 Ab, which is against IL-4Rα (referred to as M1), was used to block both IL-4 and IL-13 signaling pathways (28). This Ab was given twice weekly via i.p. injection (1 mg/mouse) as described before (29). Anti–IL-4 mAb (mAb clone 1B11) (National Institutes of Health, Bethesda, MD) was used to block IL-4 signaling pathway and was given once a week i.p. (1.5 mg/mouse). For control animals, an equivalent dose of normal control IgG (Sigma-Aldrich) was used.

**BAL, tissue fixation, and staining**

Mice were euthanized by i.p. injection of 1 ml 2.5% Avertin in PBS. The lungs were subjected to BAL extraction four times, each using 1 ml PBS through a tracheal cannula. The BAL was centrifuged at 1400 × g for 5 min to collect the cell pellet. BAL cells were resuspended in PBS containing 1% BSA and counted using a hemocytometer. Differential cell counts were performed on cytospin cell preparations stained with a modified Wright-Giemsa stain (Diff-Quik stain set; Siemens). After BAL extraction, lungs were excised completely from the chest cavity, inflated with 10% neutral buffered formalin (Fisher BioTech), and fixed at room temperature overnight in the same solution. Tissues were embedded in paraffin and sectioned and stained with periodic acid–Schiff.

**Detection of IgE, Ag-specific IgE, and CCL17/22/24 by ELISA**

High-binding 96-well ELISA plates (Costar, Corning, NY) were coated with 100 ng/well anti-mouse IgE Ab (BD Pharmingen, San Diego, CA) overnight at 4˚C. The plates were washed three times with PBS containing 0.1%Tween 20 and blocked with PBS containing 1% BSA for 1 h at 37˚C. Plates were washed, and purified IgE (BD Pharmingen) or sera were incubated in duplicate for 2 h at 37˚C. Plates were washed and incubated for 0.5 h at 37˚C in the presence of streptavidin-HRP (Sigma-Aldrich). Finally, substrate (tetramethylbenzidine) was added and incubated at room temperature in the dark. The reaction was stopped with 2 N H2SO4, OD was measured at 450 nm.

For OVA-specific IgE, plates were coated overnight with 0.2 mg/ml OVA in PBS. Plates were washed and blocked with 1% BSA-PBS for 1 h at 37˚C. Serum samples were added and plates were incubated overnight at 4˚C. Plates were washed, and biotin-conjugated anti-mouse IgE was added at a 1:500 dilution and incubated for 1 h at 37˚C. Plates were washed, incubated, and read as previously described. To detect BSA-specific IgE, plates were coated overnight with BSA and blocked with 1% BSA for 1 h at 37˚C. CCL17/22/24 ELISA reagents were purchased from R&D Systems. ELISA was performed according to the manufacturer’s instructions.

**BrdU labeling of proliferating cells in vivo**

Mice were i.p. injected with 100 μl 10 mg/ml BrdU in Dulbecco’s PBS 3 h prior to experimental end point.

**Flow cytometric analysis**

Abs for flow cytometry were purchased from BD Biosciences, eBioscience, and Serotec. Cells were washed in ice-cold flow cytometry buffer (1% [v/v] BSA and 2 mM EDTA in PBS, pH 7.5), then incubated with each Ab for 15 min and washed twice with flow cytometry buffer. MR was stained following membrane permeabilization with a Leucopert kit (Serotec) according to the manufacturer’s instructions. For detection of BrdU incorporation, cells were stained for surface markers, then fixed and permeabilized using a staining buffer set (BD Bioscience). Cells were then stained with anti-BrdU for 30 min at room temperature, or incubated first with or without DNase for 30 min at 37˚C before staining with anti-BrdU Ab. Data were acquired on a FACSCalibur flow cytometer (BD Biosciences) and analyzed with FlowJo (Tree Star).

**Statistics**

All statistical analysis was performed using GraphPad Prism 5. Unless otherwise indicated, all statistical tests are one-way ANOVA with a Tukey posthoc test with significance between groups represented as p ≤ 0.05, p ≤ 0.01, and p ≤ 0.001.

**Results**

**Overexpression of TSLP enhances recruitment and activation of aaMøs in vivo**

Our previous data indicated that elevated TSLP expression in the lung was sufficient for the development of an asthma-like chronic inflammatory airway disease (24). Mice with a lung-specific TSLP transgene (referred to as SPC-TSLP) showed increased BAL cell counts as well as marked cellular infiltration compared with control mice (24). Indeed, we found that SPC-TSLP mice recruited interstitial macrophages (IMs; Siglec-F+CD11c+CD11b+ F4/80+ and eosinophils (Eos; Siglec-F+CD11c−CD11b+ F4/80+), to the site of inflammation (Fig. 1A, Supplemental Fig. 1). Further analysis of SPC-TSLP mice showed markedly elevated expression of aaMøs.
signature markers Arg1 and Ym1 from both AMs and IMs (Fig. 1B). Additionally, AMs were polarized to an aMφ phenotype with a marked increase in the expression of MR, MHC class II and TSLPR were also increased. In contrast, TSLP did not affect the expression of M1 associated receptor, TLR2 (Fig. 1C). Reflecting the degree of cellular infiltrate, high levels of type 2 chemokines were detected, including CCL17 (memory Th2 and NKT cell chemoattractants), CCL22, and CCL24 (Eos, basophil, and mast cell chemoattractants; Fig. 1D).

**Tslpr<sup>−/−</sup> mice have impaired aMφ polarization during allergic airway inflammation**

We and other groups have shown that mice deficient in the TSLPR (Tslpr<sup>−/−</sup>) fail to develop asthma in response to inhaled Ag (24, 25). We next investigated the hypothesis that TSLP/TSLPR regulation of aMφ differentiation and type 2 chemokine production significantly contributes to allergic airway inflammation. To test this possibility, WT and Tslpr<sup>−/−</sup> mice were sensitized with OVA/Alum and later challenged for 3 consecutive days with either i.n. OVA or PBS. BAL fluids were analyzed after each challenge and chemokines were examined after the final challenge. As we reported previously (24), there was a less pronounced increase in total cells and Eos in the BAL fluid of Tslpr<sup>−/−</sup> compared with WT mice (Fig. 2A). Tissue interstitial macrophage recruitment to the lung, as well as MR expression upon OVA challenge, was decreased in Tslpr<sup>−/−</sup> mice (Fig. 2B and data not shown). WT mice sensitized and challenged with OVA had increased levels of CCL17, CCL22, and CCL24 in the BAL fluids. In contrast, there was little or no increased expression of these chemokines in OVA-sensitized and -challenged Tslpr<sup>−/−</sup> mice (Fig. 2C). Next, we isolated RNA from lungs of WT and Tslpr<sup>−/−</sup> mice 3 h after the first and second challenges, and 24 and 48 h after the final challenge, and assayed by quantitative PCR for classically and aMφ-associated genes. Arg1 and Ym1 expression was markedly reduced at all time points in Tslpr<sup>−/−</sup> mice, whereas M1 macrophage markers such as inducible NO synthase (iNOS) were increased (Fig. 2D). Taken together, these data indicate that TSLP/TSLPR signaling is pivotal in the amplification of aMφ polarization and chemokine production in allergic airway inflammation.

**TSLP administration enhances aMφ recruitment and activation in vivo**

We have developed an acute model of TSLP-induced airway inflammation in which BALB/c mice are given i.n. TSLP in the

![FIGURE 1. TSLP enhances the polarization of aMφs in vivo.](http://www.jimmunol.org/Downloadedfrom)
presence of OVA every other day for 2 wk. Mice receiving TSLP plus OVA display significant increases across all disease parameters (27). Although LPS signaling through TLR4 can induce Th2 responses to allergen in some models of mouse allergic inflammation (30), this model is independent of LPS stimulation (27). TSLP also triggered recruitment of IMs and Eos (Fig. 3A) and significant increases in aaMφ signature markers (Fig. 3B). Additionally, TSLP administration induced MR expression from IMs, whereas control protein MSA had no effect (Fig. 3C). TSLP administration in the absence of Ag failed to alter BAL cellular composition (27) or macrophage activation (Fig. 3C). Following TSLP plus OVA administration, AMs polarized to an aaMφ phenotype with marked increase in MR expression, whereas TSLPR and MHC class II were also increased (Fig. 3D). Increased expression of TSLPR and MHC class II was also observed on IMs from mice treated with TSLP plus OVA (Fig. 3E). Reflecting the cellular infiltrates, high levels of type 2 chemokines were detected. CCL17, CCL22, and CCL24 were significantly increased in mice treated with TSLP plus OVA compared with the control group (Fig. 3F). This would suggest that TSLP changes the quiescent phenotype of lung macrophages into aaMφs in vivo.

Although terminal differentiation of most mammalian cells typically results in reduced proliferative capacity, recent studies suggest that macrophage proliferation is characteristically common to various type 2 inflammatory settings (31–33). Our data raised the possibility that the large increase in macrophages seen during inflammation is the result of resident population expansion. Indeed, TSLP plus OVA treatment resulted in a dramatically increased frequency of BrdU+ AMs and IMs (Fig. 3G), as measured by a 3-h pulse of BrdU.

TSLP-induced airway inflammation and aaMφ polarization is IL-13–, but not IL-4–, dependent

The results from our experiments suggested that the effect of TSLP on aaMφs differentiation was not direct, but rather was a consequence of its ability to drive Th2 type responses. We next addressed whether blockade of these responses in a therapeutic model could control or reverse TSLP-induced disease progression and aaMφ differentiation. We used an Ab specific for the IL-4Rα-chain (M1), capable of blocking the biologic activity of both IL-4 and IL-13 (28), or an IL-4 neutralizing Ab (11B11) to block these Th2 cytokine activities during TSLP plus OVA i.n. treatment. As

**FIGURE 2.** TSLPR−/− mice show impaired aaMφ development during allergic airway inflammation. WT and Tslpr−/− mice sensitized i.p. with 50 µg OVA in 1.3 mg Alum on days 1 and 14 and challenged i.n. on days 21, 22, and 23 with 50 µg OVA. (A) Differential cell counts in BAL fluid performed 3 h after first and second OVA challenges and 24 and 48 h after final OVA challenge. (B) Cell surface markers of IMs in digested lungs analyzed by FACS. Upper panel, WT mice; lower panel, Tslpr−/− mice. One of three representative experiments in which similar results were obtained is shown. (C) CCL17, CCL22, and CCL24 concentrations in BAL fluid analyzed by ELISA. (D) Three hours after first and second OVA challenges and 24 and 48 h after final challenge. Arg1, Ym1, and iNOS expression in lungs of BALB/c and Tslpr−/− mice was analyzed by quantitative PCR. Data are representative of two independent experiments (n = 5/group). Groups of animals were compared using Student t tests. *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001.
expected, both total and Ag-specific IgE were dramatically decreased following both M1 and 11B11 Ab treatment (Supplemental Fig. 2B). Surprisingly, BAL cellularity and Eos counts were reduced after M1 but not 11B11 treatment (Supplemental Fig. 2A). Additionally, goblet cell metaplasia, mucus overproduction, as well as overall lung inflammation were suppressed only following M1 Ab treatment (data not shown). Similarly, no differences were seen for CCL17, CCL22, or CCL24 expression following 11B11 treatment (Supplemental Fig. 2C). Analysis of lung RNA levels showed that, compared with rIgG, 11B11 led to similar expression of Arg1 and Ym1 (Supplemental Fig. 2D). Additionally, aaMφ bias was shifted back in M1-treated animals with suppressed expression of CCL17, CCL22, and CCL24 (Supplemental Fig. 2C). Lung RNA analysis showed that M1 treatment reduced the expression of Arg1 and Ym1 (Supplemental Fig. 2E). These data suggest that aside from IgE production IL-4 does not play a role in TSLP-induced airway inflammation. We conclude that IL-13, but not IL-4, is required for TSLP-induced airway inflammation and differentiation of AMs toward aaMφs.

To confirm the Ab blockade studies we used mice with targeted deletions in Il4, Il13, and Stat6 genes. Stat6 is activated following either IL-4 or IL-13 exposure and is essential for the function of both cytokines and for Th2 development (34). To determine whether IL-4 or IL-13 is required for TSLP-induced pathogenesis, mice deficient in Stat6, IL-4, and IL-13 were given TSLP plus OVA as previously described. Consistent with Ab treatment, Stat6−/− mice were completely devoid of any symptoms of TSLP-mediated airway inflammation (Fig. 4A, 4B). Lungs from these
same mice lacked inflammatory infiltrates, goblet cell metaplasia, and mucus overproduction (Fig. 4B). RNA analysis showed that these mice produced less Arg1 and Ym1 (Fig. 4C) as well as CCL17, CCL22, and CCL24 in the BAL (Fig. 4D). Similar results were obtained from II13−/− mice.

In contrast to Stat6- and II13-deficient mice, II4−/− mice developed severe TSLP-mediated airway inflammation (Fig. 4A, 4B). In comparison with WT mice, lungs from II4−/− mice showed inflammatory infiltrates, goblet cell metaplasia, and mucus overproduction (Fig. 4B). They also exhibited similar expression of Arg1 and Ym1 in the lung (Fig. 4C), as well as CCL17, CCL22, and CCL24 in the BAL (Fig. 4D). Taken together, our data suggest IL-13 but not IL-4 is indispensable for TSLP-mediated airway inflammation and aaMφ activation.

**TSLP amplification of aaMφ polarization is IL-4R–dependent**

The expression of the TSLPR was examined on macrophages at the mRNA and protein levels. Quantitative RT-PCR showed that BMDMs expressed similar Tslpr mRNA levels as CD4+ T cells (Fig. 5A). Consistently, flow cytometric analysis detected TSLPR on BMDMs (Fig. 5B). Given the well-established roles of IL-4, IL-13, and the IL-4R α-chain in aaMφ differentiation (5), we evaluated the contribution of these factors to TSLP-amplified aaMφ development by culturing BMDMs from WT, II4−/−, or II4α−/− mice. TSLP alone did not induce CCL17 production; however, in the presence of IL-13 or IL-4, TSLP dramatically increased chemokine production in WT and II4−/− but not in II4α−/− macrophages (Fig. 5C). Additionally, the synergistic effect of IL-13/IL-4 with TSLP on chemokine production was inhibited by IFN-γ. Taken together, these data demonstrate that the synergistic effect of TSLP and IL-13/IL-4 on aaMφ polarization is IL-4R–dependent.

**Enhanced induction of AAMφ signature genes in K5-TSLP macrophages**

To assess whether the ability of TSLP to promote aaMφ polarization is restricted to lung macrophage populations, we analyzed macrophages from K5-TSLP mice in which TSLP is increased systemically following treatment with doxycycline (26). Analysis of cells isolated from the peritoneum of K5-TSLP mice showed an ∼10-fold increase in total cellularity, with eosinophils being the predominant cell type (Supplemental Fig. 3A). Peritoneal macrophages from doxycycline-treated K5-TSLP mice were considerably enlarged (data not shown) and displayed increased expression of MHC class II and B7-1, suggesting activation. K5-TSLP macrophages also had significant increases in MR expres-
F4/80+CD192 peritoneal macrophages were FACS-purified, after which total RNA was extracted and expression of Ym1, Arg1, and CCL17 analyzed by quantitative RT-PCR. These three genes, known to promote Th2 cytokine expression and regulate allergic inflammation (2, 5–9), were highly elevated in peritoneal macrophages isolated from doxycycline-treated transgenic mice (Supplemental Fig. 3C).

Discussion

The innate immune system is increasingly being associated with airway disease induction and progression. The local mesenchyme can also interpose signals to fine tune immune responses according to local microenvironment needs (14, 35). Macrophages are an important part of the innate immune system, but their contribution to asthma pathogenesis is not yet clear. Recent work has associated aaMΦs and their products with asthma (10). Macrophage differentiation into this phenotype occurs following exposure to IL-4, IL-13, or both. Therefore, it is not surprising that markers of alternative activation, such as AMCase, arginase, and mannose receptors, are associated with asthma (10). In a murine model of asthma, aaMΦs can contribute to disease development (36, 37). Mice with asthma have higher numbers of aaMΦs in lung tissue than do control animals, and increasing aaMΦ numbers in lung tissue by intratracheal instillation prior to inducing allergic inflammation amplifies the development of airway inflammation. Similarly, in humans, increased numbers of aaMΦs were found in the BAL fluid of patients with severe asthma compared with healthy control subjects (14). The notion of aaMΦs as an asthma modifier is also consistent with a report that demonstrated transfer of IL-4Rα+ macrophages is sufficient to promote allergic inflammation (38). However, this result was questioned in a subsequent study (39).

Emerging studies implicate TSLP, IL-25, and IL-33 as critical regulators of innate and adaptive immune responses associated with...
Th2 cytokine-mediated inflammation at mucosal sites (40). Although IL-4 and IL-13 are the prototypical direct inducers of aaMΦs, other cytokines such as IL-33 and IL-25 amplify aaMΦ induction indirectly through Th2 cells (41). IL-33 binds to ST2, a receptor for IL-33, to amplify aaMΦ induction (42). IL-25, an IL-17 family member that induces production of multipotent hemopoietic progenitors in bone marrow and GALT, gives rise to cells of monocyte/macrophage and granulocyte lineages (43). Furthermore, IL-25 reduces renal injury and inhibits colitis with induction of aaMΦs (44, 45).

Given the presence of TSLP in asthma patients, it is likely that TSLP-driven macrophage activation may contribute to clinical disease. Data presented in this study demonstrate that TSLP is a powerful enhancer of aaMΦ development during innate and adaptive immune responses. It is thought that alveolar macrophages produce suppressive cytokines such as TGF-β and inhibit the initiation of adaptive immunity to harmless Ags to avoid alveolar damage (46). However, in the presence of pathogens or damaged tissues, AMs are likely responsible for initiating inflammatory responses (47–50). In this study, we show that TSLP synergizes with endogenous IL-13/IL-4 signaling to induce the polarization of macrophages toward aaMΦs, promoting type 2 inflammation in the lung. It is also likely that parenchymal macrophages differentiate into aaMΦs in the presence of TSLP, as TSLP-treated mice showed increased MR, Arg1, and Ym1 expression. Of interest was the finding that mice with Stat6 or Il13 deficiency, but not Il4 deficiency, were completely protected from the development of TSLP-induced airway inflammation upon repeated challenge with TSLP plus OVA. Moreover, the failure to develop airway inflammation in these animals was associated with their inability to produce Th2-type cytokines or promote aaMΦ activation. To our knowledge, the present study is the first to demonstrate that signaling of IL-13, but not IL-4, plays an essential role in the development of airway inflammation and aaMΦ polarization in TSLP-induced experimental asthma. Consistent with our data, many of the observed effects seen in mice with elevated TSLP in their lungs, including fibrosis, mucus secretion, and parasitic expulsion, depend on IL-13 rather than IL-4 (1, 51). Interestingly, it has been demonstrated that Arg1 and Ym1 are dependent on IL-13Rα1 after allogenic challenge but are independent of IL-13Rα1 after IL-4 administration (52). Although recent studies have revealed considerable new information regarding the role of innate lymphoid cells in producing cytokines associated with Th2 cells that induce allergic inflammation, including IL-5 and IL-13 (53–56), their role in promoting aaMΦ induction is unclear.

Macrophage activation is a dynamic process, with the same cells initially taking part in proinflammatory and cytotoxic reactions later participating in the resolution of inflammation and wound healing (57–60). This illustrates the plasticity of macrophage differentiation and the abilities of macrophages to modulate their responses consequent to a changing microenvironment (57, 58, 61). The TSLP-enhanced polarization of macrophages toward the aaMΦ phenotype and the subsequent production of type 2 chemokines further empowers aaMΦs to recruit inflammatory cells to heighten the immune response. This process, together with the contribution of TSLP to the activation of B cells (62), dendritic cells (63, 64), Th2 cells (65, 66), basophils (67), mast cells, and NK T cells (68–70), can lead to a pathogenic outcome such as excessive type 2 inflammation or AHR.

In summary, in this study we define a previously unrecognized role for TSLP/TSLPR signaling in type 2 immunity as an important enhancer for the development of aaMΦs as well as for chemokine production. In vivo, TSLP is likely induced by a variety of antigenic and environmental stimuli in the epithelial barrier. Our findings may therefore have implications for a wide range of immune responses whereby persistent aaMΦ activation is found to play a crucial role. Because activation and recruitment of aaMΦs are dominant features in inflammatory responses associated with diseases as diverse as cancer, diabetes, and asthma, the manipulation of TSLP expression may offer novel therapeutic strategies for the treatment of multiple inflammatory conditions.

Acknowledgments

We thank the members of the Ziegler Laboratory for discussions. We specifically thank Masayuki Kitajima and Jen-Feng Lai for their valuable suggestions on FACS analysis. We thank Sylvia McCarthy for administrative assistance in the preparation of the manuscript.

Disclosures

The authors have no financial conflicts of interest.

References


Supplemental Materials

Supplemental Figure 1. Gating strategy defining eosinophils, neutrophils, alveolar macrophages (AMs) and interstitial macrophages (IMs) in the lung. Data are representative of 2 independent experiments, with 4-6 mice per group.

Supplemental Figure 2. Anti-IL-4Rα Ab (M1) but not anti-IL-4 Ab (11B11) efficiently reverses aaMΦ phenotype and allergic airway inflammation in BALB/c mice. (A) BAL counts. (B) Total serum IgE and OVA-specific IgE. (C) CCL17, CCL22 and CCL24 concentrations in BAL fluid analyzed by ELISA. (D) Quantitative RT-PCR analyses of Arg1, Ym1 and iNOS in lungs. n = 4 mice per group. NS, not significant.

Supplemental Figure 3. Peritoneal macrophages of K5-TSLP mice are abnormally activated. (A) Total counts and differential counts of peritoneal cells from transgenic mice (K5-TSLP) and normal littermate control (NLC) mice. Eosinophils were characterized as CCR3⁺SSC³ cells, B cells as CD19⁺F4/80⁻ cells, and macrophages as F4/80⁺CD19⁻ cells. (B) MFI of mannose receptor (MR) in peritoneal macrophages measured by flow cytometry. (C) Arg1, Ym1 and CCL17 production by peritoneal macrophages were analyzed by real-time PCR. Peritoneal macrophages were isolated and sorted by F4/80⁺ and CD19⁻. The fold difference of each sample relative to GAPDH level is shown. n = 5 mice per group and data are representative of two independent experiments. Groups of animals were compared using Student’s t tests. NS, not significant.
Supplemental Figure 1

- Eosinophils
- Alveolar macrophages (AMs)
- Neutrophils
- Interstitial macrophages (IMs)